Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...

Immunofluorescence microscopy A 24-year-old Hispanic female who is previously healthy presented to the hospital with ...

Dysregulation of the alternative complement pathway, hallmarked by isolated reduction of the serum C3 fraction, is now recognized as an additional feature of lupus nephritis. Persistent, isolated low ...

Patients with class III/IV LN, in which renal lesions are marked by endocapillary hypercellularity, the guideline recommends "triple therapy" with both intravenous and oral steroids, a ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

For pure Class V lupus nephritis with proteinuria greater than 1 gram daily, we propose treatment with glucocorticoids plus mycophenolate and calcineurin inhibitor therapy.

Patients were ages 18 to 75 with systemic lupus erythematosus and kidney biopsy-confirmed active class III or IV lupus nephritis, with or without concomitant class V disease.

In addition, 6% shifted to class V, 3% to class II and 6% to a no lupus nephritis classification, defined by lupus podocytopathy and/or focal segmental glomerulosclerosis.

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

REGENCY [NCT04221477] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study investigating the efficacy and safety of Gazyva® (obinutuzumab) plus standard therapy ...